Medicare Enrolled
Dr. Anjan Patel, M.D.
Medical Oncology · Sarasota, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Patel from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Patel? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Patel
Dr. Anjan Patel is a medical oncology in Sarasota, FL, with 17 years in practice. Based on federal Medicare data, Dr. Patel performed 295,732 Medicare services across 5,025 unique beneficiaries.
Between the years covered by Open Payments, Dr. Patel received a total of $10,100 from 47 pharmaceutical and/or device companies across 133 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Patel is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 17 years in practice▲ Top 5% volume in FL$ $10,100 industry payments
Medicare Practice Summary
Medicare Utilization ↗295,732
Medicare services
Top 5% in FL for medical oncology
5,025
Unique beneficiaries
$7
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~17,396 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 80,580 | $0 | $4 |
| Filgrastim injection (Zarxio) for white blood cells | 47,160 | $0 | $2 |
| Anti-nausea injection (aprepitant) | 38,220 | $1 | $5 |
| Oxaliplatin chemotherapy injection | 24,790 | $0 | $12 |
| Nivolumab injection (Opdivo) | 22,962 | $24 | $72 |
| Denosumab injection (Prolia/Xgeva) | 12,180 | $18 | $51 |
| Pembrolizumab injection (Keytruda) | 11,000 | $43 | $137 |
| Iron sucrose injection (Venofer) | 10,000 | $0 | $5 |
| Epoetin alfa injection (Procrit) for anemia | 7,090 | $6 | $23 |
| Paclitaxel chemotherapy injection | 6,216 | $0 | $2 |
| Dexamethasone injection (steroid) | 5,562 | $0 | $3 |
| Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg | 3,660 | $55 | $192 |
| Anti-nausea injection (Aloxi/palonosetron) | 3,630 | $1 | $28 |
| Complete blood count (CBC) with differential | 3,042 | $8 | $29 |
| Blood draw (venipuncture) | 2,674 | $8 | $9 |
| Injection, atropine sulfate, 0.01 mg | 2,160 | $0 | $1 |
| Office visit, established patient (30-39 min) | 2,158 | $94 | $339 |
| Injection, fluorouracil, 500 mg | 1,917 | $2 | $7 |
| Anti-nausea injection (ondansetron/Zofran) | 1,828 | $0 | $9 |
| Injection of additional new drug or substance into vein | 1,092 | $12 | $61 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 1,051 | $3 | $205 |
| Drug injection, under skin or into muscle | 957 | $10 | $69 |
| Administration of chemotherapy into vein, 1 hour or less | 647 | $97 | $378 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 387 | $22 | $84 |
| Infusion into a vein for hydration, each additional hour | 333 | $10 | $42 |
| Injection, carboplatin, 50 mg | 312 | $2 | $41 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 283 | $48 | $189 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 266 | $124 | $637 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 266 | $3 | $11 |
| Administration of additional new drug or substance into vein, 1 hour or less | 237 | $49 | $178 |
| Administration of chemotherapy into vein, each additional hour | 230 | $21 | $79 |
| Office visit, established patient (20-29 min) | 217 | $60 | $239 |
| Office visit, established patient, complex (40-54 min) | 215 | $137 | $474 |
| Infusion, normal saline solution , 1000 cc | 214 | $2 | $7 |
| Injection of drug or substance into vein | 187 | $28 | $156 |
| Injection, diphenhydramine hcl, up to 50 mg | 183 | $1 | $3 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 170 | $54 | $206 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 170 | $1 | $6 |
| Red blood count automated, with additional calculations | 154 | $5 | $20 |
| Automated urinalysis | 147 | $2 | $8 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 139 | $17 | $59 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 132 | $136 | $562 |
| Administration of chemotherapy into vein using push technique | 98 | $75 | $303 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 95 | $14 | $56 |
| Infusion into a vein for hydration, 31-60 minutes | 87 | $24 | $156 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 83 | $1 | $7 |
| Prothrombin time test (blood clotting) | 77 | $4 | $15 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 75 | $23 | $89 |
| New patient office visit (45-59 min) | 75 | $123 | $453 |
| Administration of additional new drug or substance into vein using push technique | 72 | $42 | $170 |
| Injection, zoledronic acid, 1 mg | 69 | $8 | $69 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 46 | $15 | $56 |
| New patient office visit (30-44 min) | 40 | $81 | $298 |
| Drawing of blood for a medical problem | 30 | $66 | $277 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 29 | $4 | $15 |
| New patient office visit, complex (60-74 min) | 26 | $173 | $585 |
| Red blood count, automated test | 12 | $4 | $10 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
27.9% high complexity
69.0% medium
3.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$10,100
Total received (2018-2024)
Avg $1,443/year across 7 years
Top 43% in FL for medical oncology
47
Companies
133
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$5,079 (50.3%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,371 (33.4%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,650 (16.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$1,106
2023$3,097
2022$286
2021$282
2020$77
2019$5,041
2018$212
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Boehringer Ingelheim Pharmaceuticals, Inc.
$4,666
TAIHO ONCOLOGY, INC.
$1,734
PFIZER INC.
$433
Daiichi Sankyo Inc.
$323
Merck Sharp & Dohme LLC
$319
AstraZeneca Pharmaceuticals LP
$298
Novartis Pharmaceuticals Corporation
$185
E.R. Squibb & Sons, L.L.C.
$145
Bayer Healthcare Pharmaceuticals Inc.
$142
ASD Specialty Healthcare, LLC
$127
Acerta Pharma LLC
$122
Ethicon US, LLC
$120
Inari Medical, Inc.
$115
GENZYME CORPORATION
$112
Seagen Inc.
$93
Astellas Pharma US Inc
$82
Janssen Biotech, Inc.
$79
ABBVIE INC.
$77
Takeda Pharmaceuticals U.S.A., Inc.
$76
Tactile Systems Technology Inc
$68
TerSera Therapeutics LLC
$59
Incyte Corporation
$55
Pharmacyclics LLC, An AbbVie Company
$52
GlaxoSmithKline, LLC.
$52
SUN PHARMACEUTICAL INDUSTRIES INC.
$44
Celgene Corporation
$40
Regeneron Healthcare Solutions, Inc.
$39
Sysmex Inostics Inc
$35
Lilly USA, LLC
$35
Amgen Inc.
$34
ARRAY BIOPHARMA INC
$34
Rigel Pharmaceuticals, Inc.
$32
Merz North America, Inc.
$28
JAZZ PHARMACEUTICALS INC.
$26
Sun Pharmaceutical Industries Inc.
$25
Eisai Inc.
$23
EUSA Pharma (US) LLC
$23
EMD Serono, Inc.
$23
Genmab U.S., Inc.
$19
RECORDATI_RARE_DISEASES_INC.
$18
PharmaEssentia USA Corporation
$17
Myovant Sciences Inc.
$15
Horizon Pharma plc
$14
Apellis Pharmaceuticals, Inc.
$13
Bayer HealthCare Pharmaceuticals Inc.
$13
Seattle Genetics, Inc.
$11
Veracyte, Inc.
$5
Top 3 companies account for 67.7% of total payments
Associated products mentioned in payments ›
ADCETRIS · ALIMTA · Aliqopa · BESREMI · BRAFTOVI · Bavencio · CEREZYME · CYRAMZA · Certus 140 · DARZALEX · ELITEK · ELREXFIO · EMPLICITI · ENHERTU · ENJAYMO · EPKINLY · ERLEADA · Empaveli · Enhertu · Epkinly · Erleada · FLEXITOUCH · FLOWTRIEVER CATHETER · FRUZAQLA · GILOTRIF · IMBRUVICA · INJECTAFER · INLYTA · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRYSTEXXA · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · Lenvima · MEKINIST · NINLARO · Nubeqa · OJJAARA · OPDIVO · OPDUALAG · ORGOVYX · PADCEV · PEMAZYRE · PLUVICTO · Padcev · S · SHINGRIX · SPRYCEL · SYLVANT · Sylvant · TAGRISSO · TUKYSA · Tavalisse · VENCLEXTA · VONVENDI · VOTRIENT · VPRIV · XALKORI · Xermelo · YONSA · ZEJULA · ZEPZELCA · ZOLADEX · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (50%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware.
Equivalent to $3 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
12
Per 100K population
2.7
County median income
$80,633
Nearest hospital
SARASOTA MEMORIAL HOSPITAL
2.6 mi
2.6 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Patel is a mixed practice specialist, with above-average Medicare volume (top 5% in FL), and speaking/promotional industry engagement, with 17 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Patel experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Patel performed 80,580 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Patel receive payments from pharmaceutical companies?
Yes. Dr. Patel received a total of $10,100 from 47 companies across 133 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Patel's costs compare to other medical oncologys in Sarasota?
Dr. Patel's average Medicare payment per service is $7. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Patel) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Sarasota
Browse medical oncologys in Sarasota ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in FL
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in FL
Which FL medical oncologys receive the most from drug and device companies.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc..
By company
TAIHO ONCOLOGY, INC. Payments to Doctors
See all physicians who received payments from TAIHO ONCOLOGY, INC..
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology